Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2006

View Archived Issues

Snapshots: Ceftobiprole results presented at ICAAC

Studies test in vitro antibacterial activity of retapamulin

Disease control noted with PTK-787/ZK-222584 in non-small cell lung cancer

Dose-finding study of weekly ZK-EPO in refractory solid tumors completed

Phase II data show efficacy of casopitant in chemotherapy-induced nausea/vomiting

Enrollment completed in morphine study with Hylenex

Epinastine begins phase II in patients with seasonal allergic rhinitis

Additional phase III results of telavancin in cSSSI

Entry blocker peptide demonstrates activity against influenza viruses

CoDa completes Series A financing

NitroMed focuses resources on development of BiDil XR

Ariad grants license to Bellicum for Argent cell-signaling regulation technology

Immtech advances preclinical pipeline of antimicrobial drug candidates

Analysis of independent study of CellCept in myasthenia gravis

Otsuka launching Physuline in Japan

BiovaxID accepted into E.U. Drug Register for Rare Diseases

New phase I trial of inhaled formulation of ALN-RSV01

Adherex regains all rights to ADH-1

Phase III data for Fentora for breakthrough pain in chronic low back pain patients

New agents for gastrointestinal disorders described in recent GSK patents

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Recent Janssen patent claims complement C1s inhibitors for autoimmune disorders

Nexium approved for treatment of Zollinger-Ellison syndrome

New indication sought for Herceptin in Europe

NDA filed for Sanctura XR in overactive bladder

Elan reports on the antihyperalgesic effects of their novel B1 receptor antagonist, ELN-441958

Preclinical activity of the novel antipsychotic RGH-188

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...